Press release
August 13, 2026
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
Assembly Biosciences, Inc. (ASMB)
– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross financing to support advancement of pipeline programs through key development milestones – – GS-1179